The fitness cost of a congenital heart defect shapes its genetic architecture
Ehiole Akhirome, Suk D. Regmi, Rachel A. Magnan, Nelson UgwuiD, Yidan QiniD, Claire E. SchulkeyiD, James M. CheverudiD, Patrick Y. JayiD
Abstract
BackgroundIn newborns, severe congenital heart defects are rarer than mild ones. The reason why is unknown, but presumably related to a liability threshold that rises with the severity of a defect. Because the same genetic mutation can cause different defects, other variables may contribute to pushing an individual past a defect-specific liability threshold. We consider here how variables in the genetic architecture of a heart defect depend upon its fitness cost, as defined by the likelihood of survival to reproductive age in natural history studies. MethodsWe phenotyped ~10,000 Nkx2-5+/- newborn mice, a model of human congenital heart disease, from two inbred strain crosses. Genome-wide association analyses detected loci that modify the risk of an atrial septal defect, membranous or muscular ventricular septal defect, or atrioventricular septal defect. The number of loci, heritability and quantitative effects on risk of pairwise (GxGNkx) and higher-order (GxGxGNkx) epistasis between the loci and Nkx2-5 mutation were examined as a function of the fitness cost of a defect. ResultsNkx2-5+/- mice have pleiotropic heart defects; about 70% have normal hearts. The model recapitulates the epidemiological relationship between the severity and incidence of a heart defect. Neither the number of modifier loci nor heritability depends upon the severity of a defect, but GxGNkx and GxGxGNkx effects on risk do. Interestingly, GxGxGNkx effects are three times more likely to suppress risk when the genotypes at the first two loci are homozygous and from the same, rather than opposite strains in a cross. Syn- and anti-homozygous genotypes at GxGxGNkx interactions can have an especially large impact on the risk of an atrioventricular septal defect. ConclusionsGiven a modestly penetrant mutation, epistasis contributes more to the risk of severe than mild congenital heart defect. Conversely, genetic compatibility between interacting genes, as indicated by the protective effects of syn-homozygosity at GxGxGNkx interactions, plays a newfound role in the robustness of cardiac development. The experimental model offers practical insights into the nature of genetic risk in congenital heart disease. The results more fundamentally address a longstanding question regarding how mutational robustness could arise from natural selection.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oligogenic inheritance of congenital heart disease involving a NKX2-5 modifier
Casey A. Gifford, Sanjeev S. Ranade, … Deepak Srivastava·bioRxiv·Feb 20, 2018
- Genomic and transcriptomic data analyses highlight KPNB1 and MYL4 as novel risk genes for congenital heart disease
Martin E. Broberg, Minna Ampuja, … Emmi Helle·medRxiv·Jan 7, 2022
- Quantitative trait and transcriptome analysis of genetic complexity underpinning cardiac interatrial septation in mice using an advanced intercross line
Mahdi Moradi Marjaneh, Edwin Philip Kirk, … Richard Paul Harvey·eLifePeer-reviewed·Jun 5, 2023
- Single-Cell Multimodal Profiling Reveals Maternal Diabetes-Nkx2-5 Interaction in Congenital Heart Disease in a Genetic Model Recapitulating Human Embryopathies
Stéphanie Ibrahim, Julien Maurizio, … Sonia Stefanovic·bioRxiv·Oct 13, 2026
- NKX2-5 congenital heart disease mutations show diverse loss and gain of epigenomic, biochemical and chromatin search functions underpinning pathogenicity
Alexander O. Ward, Nicole Schönrock, … Richard Paul Harvey·bioRxiv·Jun 20, 2025
- Association between the 4p16 genomic locus and different types of congenital heart disease: results from adult survivors in the UK Biobank
Aldo Córdova‐Palomera, James Rush Priest·Scientific ReportsPeer-reviewed·Nov 11, 2019